Recruiting Clinical Trials
Wet Age-Related Macular Degeneration
OPT-302-1005 Coast Study (NCT04757636) - A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
KSI301P107 Daylight Study (NCT04964089) - A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular Age-related Macular Degeneration (nAMD)
ML43000 Belvedere Study (NCT04853251) - A Phase IV, Open-Label Study of the Response to Treatment after Transition to the Port Delivery System with Ranibizumab (SUSVIMO) in Patients with Neovascular Age-Related Macular Degeneration previously treated with intravitreal agents other than Ranibizumab
RGX-314-2103 Bioreactor Study (NCT04832724) - A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered via Subretinal Delivery in Participants with Neovascular Age-related Macular Degeneration
RGX-314-2104 Atmosphere Study (NCT04704921) - A Randomized, Partially Masked, Controlled, Phase2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
UBX1325-03 Unity Study (NCT04537884) - A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration
BP41670 Burgundy Study (NCT04567303) - A Two-Part, Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7250284 Following Intravitreal Administration of Unmasked Multiple Ascending Doses and Masked Sustained Delivery From The Port Delivery System in Patients with Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
BP43445 Alluvium Study (NCT05151731)- A Phase II, Double Masked, Active Comparator Controlled Study to Investigate the Efficacy,Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Diabetic Macular Edema
Diabetic Retinopathy
BP41321 Canberra Study (NCT04265261)- A Randomized, 48-Week, Placebo-Controlled Study to Investigate the Efficacy and Safety of RG7774 in Patients with Treatment Naive Diabetic Retinopathy
Uveitis
010906IN Lumina Study (NCT03711929) - A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study (12 months) Assessing the Efficacy and Safety of Intravitreal Injections of 440 μg DE-109 (Sirolimis) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
BP40899 Dovetail Study - A Phase I, Open-Label, Multiple Ascending Dose Study to Investigator the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of RO7200220 in Monotherapy and in Combination with Ranibizumab in Patients with Diabetic or Uveitic Macular Edema
Dry Age-Related Macular Degeneration
GTSCOPE (NCT03894020) - A Study of Disease Progression in Genetically Defined Subjects with GA Secondary to Age-Related Macular Degeneration
GT005-02 Explore Study (NCT04437368) - A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
GT005-03 Horizon Study (NCT04566445) - A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
GT005-01 Focus Study (NCT03846193) - First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
Ionis Study Golden Study ISIS 696844 – CS5 (NCT03815825) - Phase 2, Randomized, Placebo-Controlled, Double-Masked Study (57 weeks) to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX
GR40973 GAllego Study (NCT03972709) - A Phase II, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163
Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, and Diabetic Macular Edema
DETeR Study (NCT04563299) - Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections